# Xu‐Chao Zhang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/xu-chao-zhang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,296 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 48 |
| i10-index | 122 |
| Last Known Institution | Guangdong Academy of Medical Sciences |
| OpenAlex ID | https://openalex.org/A5074151953 |
| ORCID iD | 0000-0002-4138-8115 |
| Works | 303 |

## Researcher papers

- [Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma](https://scholariq.org/papers/potential-predictive-value-of-i-tp53-i-and-i-kras-i-mutation-status-for-response/)
- [Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia](https://scholariq.org/papers/genome-wide-association-analysis-identifies-new-lung-cancer-susceptibility-loci/)
- [Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression](https://scholariq.org/papers/fusion-of-eml4-and-alk-is-associated-with-development-of-lung-adenocarcinomas/)
- [Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study](https://scholariq.org/papers/erlotinib-versus-gemcitabine-plus-cisplatin-as-neoadjuvant-treatment-of-stage/)
- [Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/relative-abundance-of-i-egfr-i-mutations-predicts-benefit-from-gefitinib/)
- [Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients](https://scholariq.org/papers/comprehensive-genomic-and-immunological-characterization-of-chinese-non-small/)
- [Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer](https://scholariq.org/papers/longitudinal-undetectable-molecular-residual-disease-defines-potentially-cured/)
- [Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma](https://scholariq.org/papers/genomic-landscape-and-immune-microenvironment-features-of-preinvasive-and-early/)
- [Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance](https://scholariq.org/papers/lung-adenocarcinoma-harboring-egfr-t790m-and-in-trans-c797s-responds-to/)
- [Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial](https://scholariq.org/papers/analysis-of-resistance-mechanisms-to-abivertinib-a-third-generation-egfr/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Guangdong Academy of Medical Sciences](https://scholariq.org/institutions/guangdong-academy-of-medical-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.